NASDAQ:BLCMBellicum Pharmaceuticals Stock Price, Forecast & News

$7.00

-0.37 (-5.02 %)

(As of 05/28/2020 04:00 PM ET)

Add

Compare

Today's Range

$6.92

Now: $7.00▼

$7.91

50-Day Range

$4.56

MA: $6.05▼

$7.71

52-Week Range

$3.32

Now: $7.00▼

$27.90

Volume4,704 shs

Average Volume152,779 shs

Market Capitalization$35.35 million

P/E RatioN/A

Dividend YieldN/A

Beta2.01

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Bellicum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.50, Bellicum Pharmaceuticals has a potential upside of 150.0% from its current price of $7.00.
Amount of Analyst Coverage
Bellicum Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Bellicum Pharmaceuticals has received 351 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bellicum Pharmaceuticals has received 286 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bellicum Pharmaceuticals has received 55.10% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote “Outperform” if you believe BLCM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Bellicum Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Bellicum Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bellicum Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.64% of the stock of Bellicum Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 30.12% of the stock of Bellicum Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Bellicum Pharmaceuticals are expected to decrease in the coming year, from ($9.63) to ($13.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bellicum Pharmaceuticals is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bellicum Pharmaceuticals is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.26 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:BLCM

Previous Symbol

CUSIPN/A

CIK1358403

Webwww.bellicum.com

Phone832-384-1100

Debt

Debt-to-Equity Ratio28.20

Current Ratio1.60

Quick Ratio1.60

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$7.14 million

Price / Sales4.95

Cash FlowN/A

Price / Cash FlowN/A

Book Value($1.42) per share

Price / Book-4.93

Profitability

EPS (Most Recent Fiscal Year)($19.91)

Net Income$-112,480,000.00

Net Margins-1,574.65%

Return on Equity-664.19%

Return on Assets-46.80%

Miscellaneous

Employees173

Outstanding Shares5,050,000

Market Cap$35.35 million

Next Earnings Date8/3/2020 (Estimated)

OptionableOptionable

Receive BLCM News and Ratings via Email

Sign-up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter.

Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions

How has Bellicum Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Bellicum Pharmaceuticals' stock was trading at $7.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BLCM stock has decreased by 4.0% and is now trading at $7.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bellicum Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellicum Pharmaceuticals.

When is Bellicum Pharmaceuticals' next earnings date?

Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Bellicum Pharmaceuticals.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) issued its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported $1.09 EPS for the quarter, beating the Zacks' consensus estimate of ($2.73) by $3.82. Bellicum Pharmaceuticals had a negative return on equity of 664.19% and a negative net margin of 1,574.65%. View Bellicum Pharmaceuticals' earnings history.

When did Bellicum Pharmaceuticals' stock split? How did Bellicum Pharmaceuticals' stock split work?

Shares of Bellicum Pharmaceuticals reverse split on the morning of Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for BLCM?

1 Wall Street analysts have issued 1-year target prices for Bellicum Pharmaceuticals' shares. Their forecasts range from $17.00 to $18.00. On average, they expect Bellicum Pharmaceuticals' stock price to reach $17.50 in the next year. This suggests a possible upside of 150.0% from the stock's current price. View analysts' price targets for Bellicum Pharmaceuticals.

Has Bellicum Pharmaceuticals been receiving favorable news coverage?

News articles about BLCM stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bellicum Pharmaceuticals earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutBellicum Pharmaceuticals.

Are investors shorting Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 400,200 shares, a decrease of 5.3% from the April 30th total of 422,800 shares. Based on an average daily volume of 130,000 shares, the days-to-cover ratio is currently 3.1 days. Approximately 8.1% of the shares of the stock are short sold. View Bellicum Pharmaceuticals' Current Options Chain.

Who are some of Bellicum Pharmaceuticals' key competitors?

Some companies that are related to Bellicum Pharmaceuticals include IDEAYA Biosciences (IDYA), BIOFRONTERA AG/ADR (BFRA), Zynerba Pharmaceuticals (ZYNE), AVEO Pharmaceuticals (AVEO), Rockwell Medical (RMTI), CELYAD SA/ADR (CYAD), Sierra Oncology (SRRA), Harrow Health (HROW), Savara (SVRA), AcelRx Pharmaceuticals (ACRX), Immunic (IMUX), SUMMIT THERAPEU/S (SMMT), Endonovo Therapeutics (ENDV), GlycoMimetics (GLYC) and PhaseBio Pharmaceuticals (PHAS). View all competitors.

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), Cyberark Software (CYBR), TransEnterix (TRXC), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD) and FireEye (FEYE).

Who are Bellicum Pharmaceuticals' key executives?

Bellicum Pharmaceuticals' management team includes the following people:

Mr. Richard A. Fair, Pres, CEO & Director (Age 50)
Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)
Mr. Thomas J. Farrell, Consultant (Age 56)
Mr. Atabak Mokari, Chief Financial Officer (Age 42)
Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Who are Bellicum Pharmaceuticals' major shareholders?

Bellicum Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (4.31%), Sumitomo Mitsui Trust Holdings Inc. (4.31%), Nikko Asset Management Americas Inc. (4.31%), Frazier Management LLC (2.08%), BlackRock Inc. (2.00%) and Morgan Stanley (0.49%). Company insiders that own Bellicum Pharmaceuticals stock include David M Spencer, Jon P Stonehouse, Richard A Fair and Shane Ward. View institutional ownership trends for Bellicum Pharmaceuticals.

Which major investors are selling Bellicum Pharmaceuticals stock?

BLCM stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Frazier Management LLC, BlackRock Inc., Wells Fargo & Company MN, X Square Capital LLC, and Shufro Rose & Co. LLC. View insider buying and selling activity for Bellicum Pharmaceuticals.

Which major investors are buying Bellicum Pharmaceuticals stock?

BLCM stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC, and Tower Research Capital LLC TRC . Company insiders that have bought Bellicum Pharmaceuticals stock in the last two years include Jon P Stonehouse, Richard A Fair, and Shane Ward. View insider buying and selling activity for Bellicum Pharmaceuticals.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $7.00.

How big of a company is Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals has a market capitalization of $35.35 million and generates $7.14 million in revenue each year. The biopharmaceutical company earns $-112,480,000.00 in net income (profit) each year or ($19.91) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe.

What is Bellicum Pharmaceuticals' official website?

The official website for Bellicum Pharmaceuticals is www.bellicum.com.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff